BioSpace News Archive

Business

ProQR Announces Financial Results for the Second Quarter of 2018

Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene

August 8, 2018
·
12 min read
Business

Paragon Bioservices Announces Two Key Leadership Promotions

Paragon Bioservices announces two key leadership promotions.

August 8, 2018
·
3 min read
Business

Endo Reports Second-Quarter 2018 Financial Results

Second-quarter 2018 revenues of $715 million compared to second-quarter 2017 revenues of $876 million

August 8, 2018
·
105 min read
Business

Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations

Second-Quarter Revenue of $585.3 Million

August 8, 2018
·
26 min read
Business

Ambys Medicines Launches with $140 Million to Pioneer Regenerative Medicine Therapies for Serious Liver Diseases

Ambys also announced today a strategic partnership with Takeda bringing total committed funding at launch to $140 million.

August 8, 2018
·
4 min read
Business

Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases

Partnership to support the advancement of the Ambys platform and pipeline.

August 8, 2018
·
5 min read
Augmedics Begins First-in-Human Clinical Trial of xvision-spine (XVS) Augmented-Reality Surgical Navigation System

The open label, prospective, single arm, multi-center study will evaluate the safety, performance, accuracy and usability of XVS during spine fusion procedures involving pedicle screw placement.

August 8, 2018
·
3 min read
Business

Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program

Surpassed target enrollment in Phase 2 trial of RA101495 SC for gMG

August 8, 2018
·
10 min read
FDA

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen

The applications seek to update the Prescribing Information and Summary of Product Characteristics to provide health care professionals with the option to split the first infusion of DARZALEX® over two consecutive days.

August 8, 2018
·
21 min read
Business

Opening of New Manufacturing Facility to Meet Expanding Demand for Topical Wound Oxygen (TWO2) Therapy Devices

AOTI Inc. announced the opening of an expanded manufacturing facility in Galway, Ireland for the production of its patented Topical Wound Oxygen (TWO2) therapy devices.

August 8, 2018
·
2 min read